Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.

"Declaration of competing interest AS is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead, and Avalia. DG has been a member of the advisory board of Biomerieux and Eli-Lilly and received fees for educational training or consultancy by Biogen, Cellgene, Diasorin, Janssen, QIAGEN, and Quidel. The remaining authors have no competing interests to declare."

"Funding This work was supported by National Institute of Infectious Diseases “Lazzaro Spallanzani” Line one-Ricerca Corrente on emerging infections and by Line four-Ricerca Corrente, both funded by the Italian Ministry of Health. The funders were not involved in the study design, collection, analysis, and interpretation of data, writing of this article, or the decision to submit it for publication."